AstraZeneca PLC

Pharmaceuticals and BiotechnologyFounded 1999- HQ today: Cambridge, England

Business Model Analysis

How AstraZeneca Makes Money

Q: How does AstraZeneca generate commercial revenue?

AstraZeneca generates revenue through the global discovery, clinical development, manufacturing, and commercial marketing of prescription medicines, alliance revenue shares with co-development partners (e.g., Daiichi Sankyo), and collaboration milestones.

Q: What are AstraZeneca's largest revenue-generating commercial medicines?

Farxiga/Forxiga (dapagliflozin for type 2 diabetes, heart failure and chronic kidney disease) was AstraZeneca's largest medicine in 2025 at $8.4 billion, followed by Tagrisso at $7.25 billion and Imfinzi at $6.06 billion. Ultomiris leads the rare disease portfolio and Calquence, Lynparza and Enhertu are the other main oncology contributors.

Q: How does the oncology Antibody-Drug Conjugate (ADC) partnership with Daiichi Sankyo operate?

AstraZeneca co-develops and co-commercializes breakthrough ADCs Enhertu (HER2) and datopotamab deruxtecan (Dato-DXd) with Japan's Daiichi Sankyo, sharing clinical R&D costs and splitting global net profits 50:50 outside Japan.

Q: How does the Rare Disease division (Alexion) monetize complement biology?

Alexion commercializes ultra-rare disease therapies (Soliris, Ultomiris, Voydeya) targeting paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), commanding high premium annual pricing due to life-saving clinical efficacy.

Q: What is AstraZeneca's commercial distribution model across major global markets?

AstraZeneca distributes medicines via specialty pharmaceutical distributors, wholesale channels (AmerisourceBergen, McKesson, Cardinal), hospital procurement networks, retail pharmacies, and government health authorities worldwide.

Q: How does AstraZeneca monetize cardiovascular and metabolic disease with Farxiga?

Farxiga acts as a foundational multi-indication cardiometabolic drug, driving large prescription volume across type 2 diabetes, heart failure with reduced/preserved ejection fraction, and chronic kidney disease (CKD).

Q: What is AstraZeneca's strategic manufacturing and biologics facility network?

AstraZeneca operates state-of-the-art biologics manufacturing plants in Frederick (Maryland), Södertälje (Sweden), Macclesfield (UK), and Wuxi (China), manufacturing monoclonal antibodies, small molecules, and next-generation cell therapies.

Q: How does AstraZeneca structure collaboration revenue with Merck & Co. for Lynparza?

AstraZeneca and Merck co-develop and co-commercialize PARP inhibitor Lynparza and MEK inhibitor Koselugo, sharing gross profits equally while AstraZeneca books product sales and receives contractual milestone payments.

Q: How does AstraZeneca make money?

AstraZeneca generates massive revenue by investing heavily in R&D to develop, patent, and sell high-margin specialty pharmaceuticals, specifically focusing on oncology, rare diseases, and cardiovascular medicine.

Annual Revenue: $58.7B

Executive Summary

AstraZeneca generates revenue primarily through Pharmaceuticals and Biotechnology, with roughly $58.7B in annual revenue.

Core Growth Engine: AstraZeneca's growth strategy relies on extending its existing cancer drugs into earlier stages of treatment, before the cancer spreads, which increases the number of patients who can be treated. The $39 billion acquisit...

Revenue Model & Pricing

AstraZeneca discovers, develops and sells prescription medicines, and the economics turn on patent-protected pricing funded by heavy research spending. It invested $14.2 billion in research and development in 2025, about a quarter of Total Revenue, and reported gross profit of $48.1 billion on cost of sales of $10.6 billion. Because most drug candidates fail, the company supplements internal discovery with licensing and acquisitions, from the $39 billion Alexion deal to the Daiichi Sankyo antibody-drug conjugate alliance, and shares development costs and profits with partners including Daiichi Sankyo, Amgen and Merck.

Core Revenue Streams

Product Sales

~95%

Product Sales were $55,573 million in 2025, up 9%, or about 95% of Total Revenue. This is the direct sale of AstraZeneca-manufactured prescription medicines to wholesalers, pharmacies, hospitals and government buyers. Oncology was the largest therapy area at roughly $25.6 billion of revenue, up 17%, followed by Cardiovascular, Renal and Metabolism, with Respiratory and Immunology and Rare Disease making up most of the balance.

Alliance Revenue

~5%

Alliance Revenue was $3,067 million in 2025, up 39%, or about 5% of Total Revenue. It is mostly AstraZeneca's share of profits on co-commercialised medicines, led by the Enhertu and datopotamab deruxtecan antibody-drug conjugates developed with Daiichi Sankyo, plus Tezspire with Amgen and Lynparza and Koselugo with Merck in certain markets.

Collaboration Revenue

<1%

Collaboration Revenue was $99 million in 2025, down 89% from $923 million in 2024, so less than 1% of Total Revenue. It covers upfront fees, milestone payments and royalties on out-licensed assets, and moves sharply year to year because it depends on when individual deals are signed.

Growth Strategy

AstraZeneca's growth strategy relies on extending its existing cancer drugs into earlier stages of treatment, before the cancer spreads, which increases the number of patients who can be treated. The $39 billion acquisition of Alexion Pharmaceuticals in 2021 also took it into rare diseases, where drugs treat small patient populations, carry high prices and face little generic competition.